Should antifibrinolytics be given in all patients with trauma?

被引:6
|
作者
Levi, Marcel [1 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Med, NL-1105 AZ Amsterdam, Netherlands
关键词
antifibrinolytics; hemorrhage; prohemostatic drugs; tranexamic acid; trauma; TRANEXAMIC ACID; HEMORRHAGE; THERAPY; CRASH-2; DEATH;
D O I
10.1097/ACO.0b013e3283532b29
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Purpose of review Hemorrhage is the second most important cause of death in patients with trauma, contributing to approximately 30% of trauma-related mortality. Pharmacological prohemostatic agents may be useful adjunctive treatment options in patients with severe blood loss. Recent findings Tranexamic acid was evaluated in a large international randomized controlled study in patients with trauma and severe blood loss. The drug was shown to reduce death due to bleeding, provided the treatment was given within 3 h after injury. Tranexamic acid treatment did not result in serious adverse events nor thrombotic complications. Summary In view of this efficacy and safety of this relatively cheap and simple drug, it may be recommended to put tranexamic acid in the first (maybe even prehospital) line of management of patients with severe traumatic hemorrhage.
引用
收藏
页码:385 / 388
页数:4
相关论文
共 50 条